Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 3, 2010, Pages 236-249

  Cheng, Mangeng ^a   Ott, Gregory R ^a  

^a CEPHALON INC   (United States)

Author keywords

Activating mutation; Anaplastic large cell lymphoma; Anaplastic lymphoma kinase; Chromosomal translocation; Inflammatory myofibroblastic tumor; Neuroblastoma; Non small cell lung carcinoma; Tyrosine kinase inhibitor

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; AP 26113; BMS 536394; BMS 695737; CYCLOPHOSPHAMIDE; DOXORUBICIN; GSK 1838705A; NMS E 628; NVP TAE226; NVP TAE684; PF 2361044; PREDNISOLONE; PROTEIN TYROSINE KINASE INHIBITOR; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

BREAST CANCER; CLINICAL EVALUATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG TARGETING; FATIGUE; FUSION GENE; GASTROINTESTINAL SYMPTOM; GENE AMPLIFICATION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HISTIOCYTOSIS; HUMAN; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; NEUROBLASTOMA; NONHUMAN; ONCOGENE; POINT MUTATION; PROTEIN EXPRESSION; REVIEW;

EID: 77950812741     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009030236     Document Type: Review

References (124)

1. Morris, S.W.; Kirstein, M.N.; Valentine, M.B.; Dittmer, K.G.; Shapiro, D.N.; Saltman, D.L.; Look, A.T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science, 1994, 263(5151), 1281-1284.
2. Shiota, M.; Fujimoto, J.; Semba, T.; Satoh, H.; Yamamoto, T.; Mori, S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene, 1994, 9(6), 1567-1574. (Pubitemid 24163381)
3. Iwahara, T.; Fujimoto, J.; Wen, D.; Cupples, R.; Bucay, N.; Arakawa, T.; Mori, S.; Ratzkin, B.; Yamamoto, T. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene, 1997, 14(4), 439-449. (Pubitemid 27087107)
4. Morris, S.W.; Naeve, C.; Mathew, P.; James, P.L.; Kirstein, M.N.; Cui, X.; Witte, D.P. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene, 1997, 14(18), 2175-2188.
5. Webb, T.R.; Slavish, J.; George, R.E.; Look, A.T.; Xue, L.; Jiang, Q.; Cui, X.; Rentrop, W.B.; Morris, S.W. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev. Anticancer Ther., 2009, 9(3), 331-356.
6. Bilsland, J.G.; Wheeldon, A.; Mead, A.; Znamenskiy, P.; Almond, S.; Waters, K.A.; Thakur, M.; Beaumont, V.; Bonnert, T.P.; Heavens, R.; Whiting, P.; McAllister, G.; Munoz-Sanjuan, I. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology, 2008, 33(3), 685-700.
7. Lorén, C.E.; Scully, A.; Grabbe, C.; Edeen, P.T.; Thomas, J.; McKeown, M.; Hunter, T.; Palmer, R.H. Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo. Genes Cells, 2001, 6(6), 531-544. (Pubitemid 32655385)
8. Lee, H.H.; Norris, A.; Weiss, J.B.; Frasch, M. Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature, 2003, 425(6957), 507-512. (Pubitemid 37237045)
9. Englund, C.; Lorén, C.E.; Grabbe, C.; Varshney, G.K.; Deleuil, F.; Hallberg, B.; Palmer, R.H. Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. Nature, 2003, 425(6957), 512-516. (Pubitemid 37237046)
10. Stoica, G.E.; Kuo, A.; Aigner, A.; Sunitha, I.; Souttou, B.; Malerczyk, C.; Caughey, D.J.; Wen, D.; Karavanov, A.; Riegel, A.T.; Wellstein, A. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem., 2001, 276(20), 16772-16779. (Pubitemid 37411470)
11. Stoica, G.E.; Kuo, A.; Powers, C.; Bowden, E.T.; Sale, E.B.; Riegel, A.T.; Wellstein, A. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J. Biol. Chem., 2002, 277(39), 35990-35998.
12. Moog-Lutz, C.; Degoutin, J.; Gouzi, J.Y.; Frobert, Y.; Brunet-de Carvalho, N.; Bureau, J.; Créminon, C.; Vigny, M. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J. Biol. Chem., 2005, 280(28), 26039-26048. (Pubitemid 41022195)
13. Mathivet, T.; Mazot, P.; Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase). Cell Signal., 2007, 19(12), 2434-2443. (Pubitemid 47534221)
14. Palmer, R.H.; Vernersson, E.; Grabbe, C.; Hallberg, B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem. J., 2009, 420(3), 345-361.
15. Chiarle, R.; Voena, C.; Ambrogio, C.; Piva, R.; Inghirami, G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat. Rev. Cancer, 2008, 8(1), 11-23.
16. Mano, H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci., 2008, 99(12), 2349-2355.
17. Mossé, Y.P.; Wood, A.; Maris, J.M. Inhibition of ALK signaling for cancer therapy. Clin. Cancer Res., 2009, 15(18), 5609-5614.
18. Duyster, J.; Bai, R.Y.; Morris S.W. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene, 2001, 20(40), 5623-5637. (Pubitemid 32928102)
19. Wasik, M.A.; Zhang, Q.; Marzec, M.; Kasprzycka, M.; Wang, H.Y.; Liu, X. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches. Semin. Oncol., 2009, 36(2 Suppl 1), S27-35.
20. Pulford, K.; Morris, S.W.; Turturro, F. Anaplastic lymphoma kinase proteins in growth control and cancer. J. Cell. Physiol., 2004, 199(3), 330-358. (Pubitemid 38580430)
21. Bai, R.Y.; Dieter, P.; Peschel, C.; Morris, S.W.; Duyster, J. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol. Cell Biol., 1998, 18(12), 6951-6961. (Pubitemid 28533016)
22. Bai, R.Y.; Ouyang, T.; Miething, C.; Morris, S.W.; Peschel, C.; Duyster, J. Nucleophosmin-anaplastic lymphoma kinase associated with large-cell anaplastic lymphoma activates the phophatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood, 2000, 96(13), 4319-4327.
23. Slupianek, A.; Nieborowska-Skorska, M.; Hoser, G.; Morrione, A.; Majewski, M.; Xue, L.; Morris, S.W.; Wasik, M.A.; Skorski, T. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res., 2001, 61(5), 2194-2199. (Pubitemid 32692047)
24. Kuefer, M.U.; Look, A.T.; Pulford, K.; Behm, F.G.; Pattengale, P.K.; Mason, D.Y.; Morris, S.W. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood, 1997, 90(8), 2901-2910.
25. Chiarle, R.; Gong, J.Z.; Guasparri, I.; Pesci, A.; Cai, J.; Liu, J.; Simmons, W.J.; Dhall, G.; Howes, J.; Piva, R.; Inghirami, G. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood, 2003, 101(5), 1919-1927. (Pubitemid 36237594)
26. Turner, S.D.; Tooze, R.; Maclennan, K.; Alexander, D.R. Vavpromoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene, 2003, 22(49), 7750-7761.
27. Jäger, R.; Hahne, J.; Jacob, A.; Egert, A.; Schenkel, J.; Wernert, N.; Schorle, H.; Wellmann, A. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. Anticancer Res., 2005, 25(5), 3191-3196. (Pubitemid 41105188)
28. Ergin, M.; Denning, M.F.; Izban, K.F.; Amin, H.M.; Martinez, R.L.; Saed, S.; Alkan, S. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Exp. Hematol., 2001, 29(9), 1082-1090. (Pubitemid 32780999)
29. Turturro, F.; Arnold, M.D.; Frist, A.Y.; Pulford, K. Model of inhibition of the NPM-ALK kinase activity by herbimycin A. Clin. Cancer Res., 2002, 8(1), 240-245. (Pubitemid 34101484)
30. Marzec, M.; Kasprzycka, M.; Ptasznik, A.; Wlodarski, P.; Zhang, Q.; Odum, N.; Wasik, M.A. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab. Invest., 2005, 85(12), 1544-1554.
31. Piva, R.; Chiarle, R.; Manazza, A.D.; Taulli, R.; Simmons, W.; Ambrogio, C.; D'Escamard, V.; Pellegrino, E.; Ponzetto, C.; Palestro, G.; Inghirami, G. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood, 2006, 107(2), 689-697 (Pubitemid 43076395)
32. Wan, W.; Albom, M.S.; Lu, L.; Quail, M.R.; Becknell, N.C.; Weinberg, L.R.; Reddy, D.R.; Holskin, B.P.; Angeles, T.S.; Underiner, T.L.; Meyer, S.L.; Hudkins, R.L.; Dorsey, B.D.; Ator, M.A.; Ruggeri, B.A.; Cheng, M. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood, 2006, 107(4), 1617-1623 (Pubitemid 43242400)
33. Galkin, A.V.; Melnick, J.S.; Kim, S.; Hood, T.L.; Li, N.; Li, L.; Xia, G.; Steensma, R.; Chopiuk, G.; Jiang, J.; Wan, Y.; Ding, P.; Liu, Y.; Sun, F.; Schultz, P.G.; Gray, N.S.; Warmuth, M. Identification of NVP-TAE684, a potent, selective and efficacious inhibitor of NPM-ALK. Proc. Natl. Acad. Sci. USA, 2007, 104(1), 270-275. (Pubitemid 46068021)
34. Christensen, J. G.; Zou, H.; Arango, M.; Li, Q.; Lee, J.H.; McDonnell, S.R.; Yamazaki, S.; Alton, G.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther., 2007, 6(12), 3389-3395.
35. Laurent, C.; Do, C.; Gascoyne, R.D.; Lamant, L.; Ysebaert, L.; Laurent, G.; Delsol, G.; Brousset, P. Anaplastic lymphoma kinasepositive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J. Clin. Oncol., 2009, 27(25), 4211-4216.
36. Beltran, B.; Castillo, J.; Salas, R.; Quiñones, P.; Morales, D.; Hurtado, F.; Riva, L.; Winer, E. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J. Hematol. Oncol., 2009, 2(1), 11-20.
37. Chan, J.K., Lamant, L., Algar, E., Delsol, G., Tsang, W.Y., Lee, K.C., Tiedemann, K., Chow, C.W. ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood, 2008, 112(7), 2965-2968.
38. Cessna, M.H.; Zhou, H.; Sanger, W.G.; Perkins, S.L.; Tripp, S.; Pickering, D.; Daines, C.; Coffin, C.M. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod. Pathol., 2002, 15(9), 931-938.
39. Patel, A.S.; Murphy, K.M.; Hawkins, A.L.; Cohen, J.S.; Long, P.P.; Perlman, E.J.; Griffin, C.A. RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors. Cancer Genet. Cytogenet., 2007, 176(2), 107-114
40. Panagopoulos, I.; Nilsson, T.; Domanski, H.A.; Isaksson, M.; Lindblom, P.; Mertens, F.; Mandahl, N. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int. J. Cancer, 2006, 118(5), 1181-1186. (Pubitemid 43185605)
41. Debelenko, L.V.; Arthur, D.C.; Pack, S.D.; Helman, L.J.; Schrump, D.S.; Tsokos, M. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab. Invest., 2003, 83(9), 1255-1265. (Pubitemid 37140310)
42. Debiec-Rychter, M.; Marynen, P.; Hagemeijer, A.; Pauwels, P. ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chromosomes Cancer, 2003, 38(2), 187-190. (Pubitemid 37093436)
43. Ma, Z.; Hill, D.A.; Collins, M.H.; Morris, S.W.; Sumegi, J.; Zhou, M.; Zuppan, C.; Bridge, J.A. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer, 2003, 37(1), 98-105.
44. Cools, J.; Wlodarska, I.; Somers, R.; Mentens, N.; Pedeutour, F.; Maes, B.; De Wolf-Peeters, C.; Pauwels, P.; Hagemeijer, A.; Marynen, P. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer, 2002, 34(4), 354-362. (Pubitemid 34787456)
45. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer Statistics, 2008. CA Cancer J. Clin., 2008, 58(2), 71-96.
46. Pfister, D.G.; Johnson, D.H.; Azzoli, C.G.; Sause, W.; Smith, T.J.; Baker, S. Jr; Olak, J.; Stover, D.; Strawn, J.R.; Turrisi, A.T.; Somerfield, M.R. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol., 2004, 22(2), 330-353.
47. Soda, M.; Choi, Y.L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2008, 448(7153), 561-566.
48. Choi, Y.L.; Takeuchi, K.; Soda, M.; Inamura, K.; Togashi, Y.; Hatano, S.; Enomoto, M.; Hamada, T.; Haruta, H.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Ueno, T.; Takada, S.; Yamashita, Y.; Sugiyama, Y.; Ishikawa, Y.; Mano, H. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res., 2008, 68(13), 4971-4976.
49. Takeuchi, K.; Choi, Y.L.; Togashi, Y.; Soda, M.; Hatano, S.; Inamura, K.; Takada, S.; Ueno, T.; Yamashita, Y.; Satoh, Y.; Okumura, S.; Nakagawa, K.; Ishikawa, Y.; Mano, H. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistrybased diagnostic system for ALK-positive lung cancer. Clin. Cancer Res., 2009, 15(9), 3143-3149.
50. Inamura, K.; Takeuchi, K.; Togashi, Y.; Hatano, S.; Ninomiya, H.; Motoi, N.; Mun, M.Y.; Sakao, Y.; Okumura, S.; Nakagawa, K.; Soda, M.; Choi, Y.L.; Mano, H.; Ishikawa, Y. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod. Pathol., 2009, 22(4), 508-515.
51. Wong, D.W.; Leung, E.L.; So, K.K.; Tam, I.Y.; Sihoe, A.D.; Cheng, L.C.; Ho, K.K.; Au, J.S.; Chung, L.P.; Wong, M. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer, 2009, 115(8), 1723-1733.
52. Shaw, A.T.; Yeap, B.Y.; Mino-Kenudson, M.; Digumarthy, S.R.; Costa, D.B.; Heist, R.S.; Solomon, B.; Stubbs, H.; Admane, S.; McDermott, U.; Settleman, J.; Kobayashi, S.; Mark, E.J.; Rodig, S.J.; Chirieac, L.R.; Kwak, E.L.; Lynch, T.J.; Iafrate, A.J. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol., 2009, 27(26), 4247-4253.
53. Koivunen, J.P.; Mermel, C.; Zejnullahu, K.; Murphy, C.; Lifshits, E.; Holmes, A.J.; Choi, H.G.; Kim, J.; Chiang, D.; Thomas, R.; Lee, J.; Richards, W.G.; Sugarbaker, D.J.; Ducko, C.; Lindeman, N.; Marcoux, J.P.; Engelman, J.A.; Gray, N.S.; Lee, C.; Meyerson, M.; Jänne, P.A. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res., 2008, 14(13), 4275-4283.
54. Soda, M.; Takada, S.; Takeuchi, K.; Choi, YL.; Enomoto, M.; Ueno, T.; Haruta, H.; Hamada, T.; Yamashita, Y.; Ishikawa, Y.; Sugiyama, Y.; Mano, H. A mouse model for EML4-ALK positive lung cancer. Proc. Natl. Acad. Sci. USA, 2008, 105, 19893-19897.
55. Rikova, K.; Guo, A.; Zeng, Q.; Possemato, A.; Yu, J.; Haack, H.; Nardone, J.; Lee, K.; Reeves, C.; Li, Y.; Hu, Y.; Tan, Z.; Stokes, M.; Sullivan, L.; Mitchell, J.; Wetzel, R.; Macneill, J.; Ren, J.M.; Yuan, J.; Bakalarski, C.E.; Villen, J.; Kornhauser, J.M.; Smith, B.; Li, D.; Zhou, X.; Gygi, S.P.; Gu, T.L.; Polakiewicz, R.D.; Rush, J.; Comb, M.J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 2007, 131(6), 1190-1203.
56. Lin, E.; Li, L.; Guan, Y.; Soriano, R.; Rivers, C.S.; Mohan, S.; Pandita, A.; Tang, J.; Modrusan, Z. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol. Cancer Res., 2009, 7(9), 1466-1476.
57. Maris, J.M.; Hogarty, M.D.; Bagatell, R.; Cohn, S.L. Neuroblastoma. Lancet, 2007, 369(9579), 2106-2120.
58. Park, J.R.; Eggert, A.; Caron, H. Neuroblastoma: biology, prognosis, and treatment. Pediatr. Clin. North Am., 2008, 55(1), 97-120.
59. Mossé, Y.P.; Laudenslager, M.; Longo, L.; Cole, K.A.; Wood, A.; Attiyeh, E.F.; Laquaglia, M.J.; Sennett, R.; Lynch, J.E.; Perri, P.; Laureys, G.; Speleman, F.; Kim, C.; Hou, C.; Hakonarson, H.; Torkamani, A.; Schork, N.J.; Brodeur, G.M.; Tonini, G.P.; Rappaport, E.; Devoto, M.; Maris, J.M. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature, 2008, 455(7215), 930-936.
60. Chen, Y.; Takita, J.; Choi, Y.L.; Kato, M.; Ohira, M.; Sanada, M.; Wang, L.; Soda, M.; Kikuchi, A.; Igarashi, T.; Nakagawara, A.; Hayashi, Y.; Mano, H.; Ogawa, S. Oncogenic mutations of ALK kinase in neuroblastoma. Nature, 2008, 455(7215), 971-974.
61. George, R.E.; Sanda, T.; Hanna, M.; Fröhling, S.; Luther, W.; Zhang, J.; Ahn, Y.; Zhou, W.; London, W.B.; McGrady, P.; Xue, L.; Zozulya, S.; Gregor, V.E.; Webb, T.R.; Gray, N.S.; Gilliland, D.G.; Diller, L.; Greulich, H.; Morris, S.W.; Meyerson, M.; Look, A.T. Activating mutations in ALK provide a therapeutic target in neuroblastoma, Nature, 2008, 455(7215), 975-978.
62. Janoueix-Lerosey, I.; Lequin, D.; Brugières, L.; Ribeiro, A.; de Pontual, L.; Combaret, V.; Raynal, V.; Puisieux, A.; Schleiermacher, G.; Pierron, G.; Valteau-Couanet, D.; Frebourg, T.; Michon, J.; Lyonnet, S.; Amiel, J.; Delattre, O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature, 2008, 455(7215), 967-970.
63. McDermott, U.; Iafrate, A.J.; Gray, N.S.; Shioda, T.; Classon, M.; Maheswaran, S.; Zhou, W.; Choi, H.G.; Smith, S.L.; Dowell, L.; Ulkus, L.E.; Kuhlmann, G.; Greninger, P.; Christensen, J.G.; Haber, D.A.; Settleman, J. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res., 2008, 68(9), 3389-3395.
64. Lamant, L.; Pulford, K.; Bischof, D.; Morris, S.W.; Mason, D.Y.; Delsol, G.; Mariamé, B. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am. J. Pathol., 2000, 156(5), 1711-1721. (Pubitemid 30646709)
65. Miyake, I.; Hakomori, Y.; Shinohara, A.; Gamou, T.; Saito, M.; Iwamatsu, A.; Sakai, R. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene, 2002, 21(38), 5823-5834. (Pubitemid 35007232)
66. Passoni, L.; Longo, L.; Collini, P.; Coluccia, A.M.; Bozzi, F.; Podda, M.; Gregorio, A.; Gambini, C.; Garaventa, A.; Pistoia, V.; Del Grosso, F.; Tonini, G.P.; Cheng, M.; Gambacorti-Passerini, C.; Anichini, A.; Fossati-Bellani, F.; Di Nicola, M.; Luksch, R. Mutation- independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res., 2009, 69(18), 7338-7346.
67. Mentlein, R.; Held-Feindt, J. Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas. J. Neurochem., 2002, 83(4), 747-753.
68. Lu, K.V.; Jong, K.A.; Kim, G.Y.; Singh, J.; Dia, E.Q.; Yoshimoto, K.; Wang, M.Y.; Cloughesy, T.F.; Nelson, S.F.; Mischel, P.S. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J. Biol. Chem., 2005, 280(29), 26953-26964.
69. Powers, C.; Aigner, A.; Stoica, G.E.; McDonnell, K.; Wellstein, A. Pleiotrophin signaling through anaplastic lymphoma kinase is ratelimiting for glioblastoma growth. J. Biol. Chem., 2002, 277 (16), 14153-14158. (Pubitemid 34968027)
70. Li, R.; Morris, S.W. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med. Res. Rev., 2008, 28(3), 372-412.
71. An investigational drug, PF-02341066 is being studied versus standard of care in patients with advanced non-small cell lung cancer with a specific gene profile involving the anaplastic lymphoma kinase (ALK) gene, NCT00932893, Phase III. www. clincaltrials.gov, 2009.
72. PF-02341066 in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma, NCT00939770, Phase I/II. www.clincaltrials.gov, 2009.
73. Zou, H.Y.; Qiuhua, L.; Lee, J.H.; Arango, M.E.; McDonnell, S.R.; Yamazaki, S.; Koudriakova, T.B.; Alton, G.; Cui, J.; Kung, P.P.; Nambu, M.D.; Los, G.; Bender, S.; Mroczkowski, B.; Christensen, J.G. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res., 2007, 67(9), 4408-4417.
74. Cui, J. J. Preparation of aminoheteroaryl compounds as protein kinase inhibitors. PCT Int. Appl. WO2004076412, 2004.
75. Cui, J.J.; Funk, L.A.; Jia, L.; Kung, P.P.; Meng, J. J.; Nambu, M.D.; Pairish, M.A.; Shen, H.; Tran-Dube, M.B. Preparation of aminoheteroaryl compounds as c-Met tyrosine kinase inhibitors. PCT Int. Appl. WO2006021886, 2006.
76. Yamazaki, S.; Skaptason, J.; Romero, D.; Lee, J.H.; Zou, H.Y.; Christensen, J.G.; Koup, J.R.; Smith, B.J.; Koudriakova, T. Pharmacokinetic- pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab. Dispos., 2008, 36(7), 1267-1274. (Pubitemid 351929310)
77. Kwak, E.L.; Camidge, D.R.; Clark, J.; Shapiro, G.I.; Maki, R.G.; Ratain, M.J.; Solomon, B.; Bang, Y.; Ou, S.; Salgia, R. In clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J. Clin. Oncol., 2009 Annual Meeting Proceedings (Post-Meeting Edition) 27, 15S, 3509.
78. Liu, T.-J.; LaFortune, T.; Honda, T.; Ohmori, O.; Hatakeyama, S.; Meyer, T.; Jackson, D.; de Groot, J.; Yung, W. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol. Cancer Ther., 2007, 6(4), 1357-1367. (Pubitemid 46711999)
79. Garcia-Echeverria, C.; Kanazawa, T.; Kawahara, E.; Masuya, K.; Matsuura, N.; Miyake, T.; Ohmori, O.; Umemura, I.; Steensma, R.; Chopiuk, G.; Jiang, J.; Wan, Y.; Ding, Q.; Zhang, Q.; Gray, N.S.; Karanewsky, D. Preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. PCT Int. Appl. WO2005016894, 2005.
80. Gray, N.S.; Michellys, P.Y.; Pei, W.; Marsilje, T.H.; Lu, W.; Chen, B.; Uno, T.; Jin, Y.; Jiang, T. Preparation of 2-(Het)arylamino-6-aminopyridine derivatives and fused forms thereof as kinase inhibitors for treating hyperproliferative and angiogenesis disorders. PCT Int. Appl. WO2009032703, 2009.
81. Marsilje, T.H.; Lu, W.; Chen, B.; He, X.; Bursulaya, B.; Lee, C.C.H.; Gray, N.S. Pyrimidine derivatives as IGF-1R and ALK inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. PCT Int. Appl. WO2009032668, 2009.
82. Chen, B.; Jiang, T.; Marsilje, T.H.; Michellys, P.Y.; Nguyen, T.N.; Pei, W.; Wu, B.; Gao, Z.; Ge, Y.; Huang, C.; Li, Y. Preparation of pyrimidine derivatives as protein kinase inhibitors for treating proliferative disorders, immune disorders, and infections. PCT Int. Appl. WO2009126515, 2009.
83. Jiang, T.; Michellys, P.Y.; Nguyen, T.N.; Pei, W.; Wu, B.; Zhu, X. Preparation of triazine and pyrimidine derivatives as kinase inhibitors. PCT Int. Appl. WO2009126514, 2009.
84. Patnaik, S.; Stevens, K.L.; Gerding, R.; Deanda, F.; Shotwell, J. B.; Tang, J.; Hamajima, T.; Nakamura, H.; Leesnitzer, M.A.; Hassell, A.M.; Shewchuck, L.M.; Kumar, R.; Lei, H.; Chamberlain, S.D. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase. Bioorg. Med. Chem. Lett., 2009, 19(11), 3136-3140.
85. Chamberlain, S.D.; Wilson, J.W.; Deanda, F.; Patnaik, S.; Redman, A.M.; Yang, B.; Shewchuk, L.; Sabbatini, P.; Leesnitzer, M.A.; Groy, A.; Atkins, C.; Gerding, R.; Hassell, A.M.; Lei, H.; Mook, R. A.; Jr., Moorthy, G.; Rowand, J.L.; Stevens, K.L.; Kumar, R.; Shotwell, J. B. Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: Potent inhibitors of the IGF-1R receptor tyrosine kinase. Bioorg. Med. Chem. Lett., 2009, 19(2), 469-473.
86. Chamberlain, S.D.; Redman, A.M.; Wilson, J.W.; Deanda, F.; Shotwell, J.B.; Gerding, R.; Lei, H.; Yang, B.; Stevens, K.L.; Hassell, A.M.; Shewchuk, L.M.; Leesnitzer, M. A.; Smith, J.L.; Sabbatini, P.; Atkins, C.; Groy, A.; Rowand, J.L.; Kumar, R.; Mook, R. A.; Moorthy, G., Patnaik, S. Optimization of 4,6-bis-anilino-1Hpyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity. Bioorg. Med. Chem. Lett., 2009, 19(2), 360-364.
87. Sabbatini, P.; Korenchuk, S.; Rowand, J.L.; Groy, A.; Liu, Q.; Leperi, D.; Atkins, C.; Dumble, M.; Yang, J.; Anderson, K.; Kruger, R.G.; Gontarek, R.R.; Maksimchuk, K.R.; Suravajjala, S.; Lapierre, R.R.; Shotwell, J.B.; Wilson, J.W.; Chamberlain, S.D.; Rabindran, S.K.; Kumar, R. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol. Cancer Ther., 2009, 8(10), 2811-2820.
88. Ott, G.R.; Cheng, M.; Tripathy, R.; McHugh, R.; Weinberg, L.; Milkiewicz, K.L.; Anzalone, A.V.; Underiner, T.J.; Curry, M.A.; Breslin, H.J.; Quail, M.R.; Lu, L.; Wan, W.; Angeles, T.S.; Albom, M.S.; Aimone, L.; Ator, M.A.; Ruggeri, B.A.; and Dorsey, B.D. Discovery of a potent, selective, orally bioavailable inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity in animal models of anaplastic large-cell lymphoma. AACR Translational Cancer Medicine 2008: Bridging the Lab and the Clinic in Cancer Medicine, November, 2008.
89. Lu, L.; Ghose, A.K.; Quail, M.R.; Albom, M.S.; Durkin, J.T.; Holskin, B.P.; Angeles, T.S.; Meyer, S.L.; Ruggeri, B.A.; Cheng, M. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. Biochemistry, 2009, 48(16), 3600-3609.
90. Quail, M.R.; Lu, L.; Ghose, M.; Wan, W.; Ott, G.; Dorsey, B.D.; Ruggeri, B.A.; Cheng, M. In vitro Activity and in vivo Efficacy of a Benzazepinone ALK Inhibitor in EML4-ALK Positive and Negative Non-Small Cell Lung Cancer Cells. Proceeding of American Association for Cancer Research, Abstract # 3735, April, 2009.
91. Lu. L.; Quail, M.R.; Jones, M.; Ghose, M.; DeVine, A.; Ott, G.R.; Jones-Bolin, S.; Dorsey, B.D.; Ruggeri, B.A.; Cheng, M. In vitro Activity and in vivo Efficacy of a Benzazepinone ALK Inhibitor on Human Neuroblastoma-derived Cell Lines. Proceeding of American Association for Cancer Research, Abstract # 3736, April, 2009.
92. Shakespeare, W.C.; Fantin, V.R.; Wang, F.; Kohlmann, A.; Liu, S.; Huang, W.S.; Wang, Y.; Zou, D.; Thomas, M.; Li, F.; Qi, J.; Cai, L.; Dwight, T.; Xu, Y.; Xu, R.; Dodd, R.; Xu, Q.; Anjum, R.; Zhang, S.; Keats, J.; Xue, L.; Wardwell, S.D.; Ning, Y.; Moran, L.E.; Mohemmad, Q.K.; Zhu, X.; Narasimhan, N.I.; Rivera, V.M.; Dalgarno, D.; Clackson, T. Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK). Proceeding of American Association for Cancer Research, Abstract # 3738, April, 2009.
93. Wang, Y.; Huang, W.S.; Liu, S.; Shakespeare, W.C.; Thomas, R. M.; Qi, J.; Li, F.; Zhu, X.; Kohlmann, A.; Dalgarno, D.C.; Romero, J.A.C.; Zou, D. Phosphorus derivatives as kinase inhibitors. PCT Int. Appl. WO2009143389, 2009.
94. Ardini, E.; Menichincheri, M.; De Ponti, C.; Amboldi, N.; Ballinari, D.; Saccardo, M.B.; Croci, V.; Stellari, F.; Texido, G.; Orsini, P.; Perrone, E.; Bandiera, T.; Borgia, A. L.; Lansen, J.; Isacchi, A.; Colotta, F.; Pesenti, E.; Magnaghi, P.; Galvani, A. A highly potent, selective and orally available ALK inhibitor with demonstrated antitumor efficacy in ALK dependent lymphoma and non small cell lung cancer models. Proceeding of American Association for Cancer Research, Abstract # 3737, April, 2009.
95. Fancelli, D.; Moll, J.; Varasi, M.; Bravo, R.; Artico, R.; Berta, D.; Bindi, S.; Cameron, A.; Candiani, I.; Cappella, I.P.; Carpinelli, P.; Croci, W.; Forte, B.; Giorgini, M.L.; Klapwijk, J.; Marsiglio, A.; Pesenti, E.; Rocchetti, M.; Roletto, F.; Severino, D.; Soncini, C.; Storici, P.; Tonani, R.; Zugnoni, P.; Vianello,P. 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem., 2006, 49(24), 7247-7251.
96. Li, R.; Xue, L.; Zhu, T.; Jiang, Q.; Cui, X.; Yan, Z.; McGee, D.; Wang, J.; Gantla, V.R.; Pickens, J.C.; McGrath, D.; Chucholowski, A.; Morris, S.W.; Webb, T.R. Design and synthesis of 5-Arylpyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. J. Med. Chem., 2006, 49(3), 1006-1015. (Pubitemid 43221648)
97. Gregor, V.E.; Liu, Y.; Anikin, A.I.; McGee, D.P.C.; Mikel, C.; McGrath, D.E.; Vavilala, G.R.; Pickens, J.C.; Kadushkin, A.; Thiruvazhi, M.S.; Zozulya, S.; Vairagoundar, R.; Zhu, T.; Chucholowski, A.; Webb, T.R.; Jiang, L.; Gantla, V.R.; Yan, Z. Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders. PCT Int. Appl. WO2008021369, 2008.
98. Gregor, V.E.; Liu, Y.; Anikin, A.; Mikel, C.; McGrath, D.E.; Vavilala, G.R.; Pickens, J.C.; Kadushkin, A.; Jiang, L.; Thiruvazhi, M.S.; Zozulya, S.; Vairagoundar, R.; Zhu, T.; Chucholowski, A.; Yan, Z.; Khasanov, A. Preparation of imidazo[4,5-f]isoindole derivatives as tyrosine kinase inhibitors. PCT Int. Appl. WO2009117097, 2009.
99. Wittman, M.; Carboni, J.; Attar, R.; Balasubramanian, B.; Balimane, P.; Brassil, P.; Beaulieu, F.; Chang, C.; Clarke, W.; Dell, J.; Eummer, J.; Frennesson, D.; Gottardis, M.; Greer, A.; Hansel, S.; Hurlburt, W.; Jacobson, B.; Krishnananthan, S.; Lee, F.Y.; Li, A.; Lin, T.A.; Liu, P.; Ouellet, C.; Sang, X.; Saulnier, M.G.; Stoffan, K.; Sun, Y.; Velaparthi, U.; Wong, H.; Yang, Z.; Zimmermann, Z.; Zoeckler, M.; Vyas, D. Discovery of a 1H-Benzoimidazol-2-yl) -1H-pyridin-2-one (BMS-536924) Inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J. Med. Chem., 2005, 48(18), 5639-5643.
100. Velaparthi, U.; Wittman, M.; Liu, P.; Carboni, J.M.; Lee, F.Y.; Attar, R.; Balimane, P.; Clarke, W.; Sinz, M.W.; Hurlburt, W.; Patel, K.; Discenza, L.; Kim, S.; Gottardis, M.; Greer, A.; Li, A.; Saulnier, M.; Yang, Z.; Zimmermann, K.; Trainor, G.; Vyas, D. Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol- 1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d] imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity. J. Med. Chem., 2008, 51(19), 5897-5900.
101. Velaparthi, U.; Wittman, M.; Liu, P.; Stoffan, K.; Zimmermann, K.; Sang, X.; Carboni, J.; Li, A.; Attar, R.; Gottardis, M.; Greer, A.; Chang, C.Y.; Jacobsen, B.L.; Sack, J.S.; Sun, Y.; Langley, D.R.; Balasubramanian, B.; Vyas, D. Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R). Bioorg. Med. Chem. Lett., 2007, 17(8), 2317-2321.
102. Duffaud, F.; Le Cesne, A. Imatinib in the treatment of solid tumours. Target Oncol., 2009, 4(1), 45-56.
103. Patnaik, M.M.; Tefferi, A.; Pardanani, A. Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr. Cancer Drug Targets, 2007, 7(5), 492-503.
104. Advani, A.S. C-kit as a target in the treatment of acute myelogenous leukemia. Curr. Hematol. Rep., 2005, 4(1), 51-58.
105. Hao, H.; Naomoto, Y.; Bao, X.; Watanabe, N.; Sakurama, K.; Noma, K.; Motoki, T.; Tomono, Y.; Fukazawa, T.; Shirakawa, Y.; Yamatsuji, T.; Matsuoka, J.; Wang, Z.G.; Takaoka, M. Focal adhesion kinase as potential target for cancer therapy. Oncol. Rep., 2009, 22(5), 973-979.
106. Brunton, V.G.; Frame, M.C. Src and focal adhesion kinase as therapeutic targets in cancer. Curr. Opin. Pharmacol., 2008, 8(4), 427-432.
107. Chitnis, M.M.; Yuen, J.S.; Protheroe, A.S.; Pollak, M.; Macaulay, V.M. The type 1 insulin-like growth factor receptor pathway. Clin. Cancer Res., 2008, 14(20), 6364-6370.
108. Hewish, M.; Chau, I.; Cunningham, D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat. Anticancer Drug Disc., 2009, 4(1), 54-72.
109. Shi P.; Lai R.; Lin Q.; Iqbal A.S.; Young L.C.; Kwak L.W.; Ford R.J.; Amin H.M. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood, 2009, 114(2), 360-370.
110. Espinal, J. What is the role of the insulin receptor tyrosine kinase? Trends. Biochem. Sci., 1988, 13(10), 367-368.
111. Saltiel, A.R. Putting the brakes on insulin signaling. N. Engl. J. Med., 2003, 349(26), 2560-2562.
112. Pirola, L.; Johnston A.M.; Van Obberghen E. Modulation of insulin action. Diabetologia, 2004, 47(2), 170-184.
113. Horn, L.; Pao, W. EML4-ALK: honing in on a new target in nonsmall-cell lung cancer. J. Clin. Oncol., 2009, 27(26), 4232-4235.
114. Martelli, M.P.; Sozzi, G.; Hernandez, L.; Pettirossi, V.; Navarro, A.; Conte, D.; Gasparini, P.; Perrone, F.; Modena, P.; Pastorino, U.; Carbone, A.; Fabbri, A.; Sidoni, A.; Nakamura, S.; Gambacorta, M.; Fernández, P.L.; Ramirez, J.; Chan, J.K.; Grigioni, W.F.; Campo, E.; Pileri, S.A.; Falini B. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am. J. Pathol., 2009, 174(2), 661-670.
115. Boland, J.M.; Erdogan, S.; Vasmatzis, G.; Yang, P.; Tillmans, L.S.; Johnson, M.R.; Wang, X.; Peterson, L.M.; Halling, K.C.; Oliveira, A.M.; Aubry, M.C.; Yi, E.S. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum. Pathol., 2009, 40(8), 1152-1158.
116. Shah, N.P.; Sawyers, C.L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene, 2003, 22(47), 7389-7395.
117. O'Hare, T.; Eide, C.A.; Deininger, M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to the cure for chronic myeloid leukemia. Blood, 2007, 110(7), 2242-2249.
118. Engelman, J.A.; Settleman, J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev., 2008, 18(1), 1-7.
119. Liu, J.; Joha, S.; Idziorek, T.; Corm, S.; Hetuin, D.; Philippe, N.; Preudhomme, C.; Quesnel, B. BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism, Leukemia, 2008, 22(4), 791-799. (Pubitemid 351552628)
120. Desai, J.; Shankar, S.; Heinrich, M.C.; Fletcher, J.A.; Fletcher, C.D.; Manola, J.; Morgan, J.A.; Corless, C.L.; George, S.; Tuncali, K.; Silverman, S.G.; Van den Abbeele, A.D.; van Sonnenberg, E.; Demetri, G.D. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin. Cancer Res., 2007, 13(18), 5398-5405.
121. Corless, C.L.; Schroeder, A.; Griffith, D.; Town, A.; McGreevey, L.; Harrell, P.; Shiraga, S.; Bainbridge, T.; Morich, J.; Heinrich, M.C. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol., 2005, 23(23), 5357-5364.
122. Engelman, J.A.; Janne, P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer. Clin. Cancer Res., 2008, 14(10), 2895-2899.
123. Shah, N. P.; Tran, C.; Lee, F.Y.; Chen P.; Norris, D.; Sawyers, C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 2004, 305(5682), 399-401.
124. Kantarjian, H.; Giles, F.; Wunderle, L.; Bhalla, K.; O'Brien, S.; Wassmann, B.; Tanaka, C.; Manley, P.; Rae, P.; Mietlowski, W.; Bochinski, K.; Hochhaus, A.; Griffin, J.D.; Hoelzer, D.; Albitar, M.; Dugan, M.; Cortes, J.; Alland, L.; Ottmann O.G. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med., 2006, 354(24), 2542-2551. (Pubitemid 43882350)